<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03435744</url>
  </required_header>
  <id_info>
    <org_study_id>PILL-DepSTAT-001</org_study_id>
    <nct_id>NCT03435744</nct_id>
  </id_info>
  <brief_title>Simvastatin as an Augmentation Treatment for Treatment Resistant Depression: Randomized Controlled Trial.</brief_title>
  <acronym>DepSTAT</acronym>
  <official_title>A Multicentre 12-week Randomised, Double Blind, Placebo Controlled Trial of Simvastatin as Augmentation Treatment for Treatment-resistant Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pakistan Institute of Living and Learning</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pakistan Institute of Living and Learning</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this double blind, randomized placebo controlled trial we aim to determine the efficacy of
      simvastatin as an add-on treatment for treatment resistant depression. We will recruit 150
      people with treatment-resistant depression with the aim of determining whether the addition
      of simvastatin (20mg daily) to treatment as usual (TAU) for 12 weeks leads to an improvement
      in depressive symptom compared with placebo added to TAU.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1-Simvastatin plus TAU, 2- Placebo plus TAU</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind plcaebo controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Montgomery-Asberg Depression Rating Scale (MADRS; Montgomery Asberg, 1979)</measure>
    <time_frame>Week-2, Week-4, Week-8 and Week-12</time_frame>
    <description>The MADRS will be used as primary outcome measure in estimating depression severity</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Simvastatin with TAU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive Simvastatin 20 mg added to TAU for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Tablet with TAU</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo added to TAU for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin 20 mg</intervention_name>
    <description>Simvastatin 20 mg added to TAU for 3 months.</description>
    <arm_group_label>Simvastatin with TAU</arm_group_label>
    <other_name>Statins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Matched placebo added to TAU for 3 months</description>
    <arm_group_label>Placebo Oral Tablet with TAU</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-5 current major depressive episode

          -  Must currently be on an antidepressant and must have had a non-response to &gt;2 oral
             antidepressant treatments in the current episode (including the one they are currently
             taking).

          -  Capacity to give informed consent

          -  Willing to use adequate contraception

          -  Give written informed consent

        Exclusion Criteria:

          -  Primary psychotic or bipolar disorder

          -  History of intolerance to statins or presence of any contraindication to statins

          -  Presence of any serious medical condition or neurological problem

          -  Presence of autoimmune or inflammatory disorder

          -  Alcohol or drug dependence

          -  Active suicidal ideation

          -  Pregnant or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Muhammad I Husain</last_name>
    <phone>+14165358501</phone>
    <phone_ext>37838</phone_ext>
    <email>ishrat.husain@camh.ca</email>
  </overall_contact>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 9, 2018</study_first_submitted>
  <study_first_submitted_qc>February 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2018</study_first_posted>
  <last_update_submitted>February 9, 2018</last_update_submitted>
  <last_update_submitted_qc>February 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

